Haemonetics Corporation 10-Q Summary
Business Context and Reporting Period
Company: Haemonetics Corporation
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 27, 2008 (Second Quarter of Fiscal Year 2009)
Business Overview: Haemonetics designs, manufactures, and markets automated blood management solutions, including devices and disposables for blood donors and patients, as well as software and services for blood and plasma collection centers.
Key Financial Metrics
| Metric (in thousands) | Q2 FY2009 (3 Months) |
Q2 FY2008 (3 Months) |
YTD FY2009 (6 Months) |
YTD FY2008 (6 Months) |
|---|---|---|---|---|
| Net Revenues | $145,919 | $121,179 | $290,035 | $243,115 |
| Gross Profit | $74,689 | $59,889 | $147,726 | $121,383 |
| Gross Margin | 51.2% | 49.4% | 50.9% | 49.9% |
| Operating Income | $23,609 | $14,616 | $42,943 | $30,395 |
| Operating Margin | 16.2% | 12.1% | 14.8% | 12.5% |
| Net Income | $14,807 | $11,167 | $29,148 | $23,844 |
| Diluted EPS | $0.57 | $0.42 | $1.11 | $0.89 |
| Cash & Equivalents | $111,331 (as of Sept 27, 2008) | |||
| Working Capital | $254,282 (as of Sept 27, 2008) | |||
| Net Cash Position | $97,579 (Cash less Total Debt) |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 20.4% in Q2 and 19.3% YTD compared to the prior year. Approximately 5.5% of the Q2 increase was attributable to favorable foreign exchange rates; the remainder was driven by volume growth in disposables and equipment sales.
- Profitability: Operating income surged 61.5% in Q2 and 41.3% YTD. Gross margin improved by 180 basis points Q2-over-Q2, driven by price increases and the higher-margin TEG business, partially offset by a shift toward lower-margin plasma products.
- Acquisitions: Growth was bolstered by the TEG Thrombelastograph business (acquired Q3 FY2008) and the Medicell business (acquired Q1 FY2009), contributing $4.7 million and $9.7 million in revenue for Q2 and YTD, respectively.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses increased 19.0% in Q2, largely due to integration costs from recent acquisitions and higher performance-based compensation. R&D expenses decreased 22.4% due to lower spending on core technology projects.
- Cash Flow: Net cash provided by operating activities increased to $41.8 million YTD (from $22.1 million prior year). Net cash used in financing activities decreased significantly to $33.8 million YTD, primarily due to the completion of a $60 million share repurchase program.
Guidance, Outlook, and Risks
- Restructuring: Management announced a transformation of the Technical Operations organization. The company expects to incur total exit-related costs of $5 million to $7 million over fiscal year 2009. $2.1 million in one-time costs were incurred in the first six months.
- Product Outlook: Plasma disposable growth rates are expected to moderate to a low double-digit rate as market share growth trends down. The company is focusing on the TEG diagnostic platform and OrthoPAT adoption.
- Share Repurchases: The company completed a $60 million share repurchase program in the first six months of FY2009, purchasing approximately 1.1 million shares.
- Tax Rate: The effective tax rate for the six months ended Sept 27, 2008, was 32.4%. This included discrete benefits from the expiration of statutes of limitations in Japan. The reinstatement of the federal R&D credit (enacted Oct 3, 2008) is expected to benefit the tax rate in Q3 FY2009.
- Risks: Key risks include foreign currency fluctuations (approx. 54% of sales are international), raw material costs (plastics), regulatory changes, and the impact of industry consolidation in the plasma market.
Investor Verification Checklist
- Acquisition Integration: Verify the timeline and cost realization of the TEG and Medicell acquisitions to ensure projected synergies are met.
- Plasma Market Dynamics: Monitor the moderation of plasma growth rates and the impact of industry consolidation on Haemonetics' market share.
- Restructuring Costs: Track the remaining $3 million to $5 million in expected restructuring costs for FY2009 and their impact on future operating margins.
- Foreign Exchange Exposure: Assess the sensitivity of future earnings to fluctuations in the Euro and Japanese Yen, given that over half of revenue is generated outside the U.S.
- Capital Allocation: Confirm the status of future capital expenditures and whether the company will initiate a new share repurchase program following the completion of the $60 million program.